Kornimate/medical-research-clean huggingface dataset:
trans-abdominal fetal pulse oximetry: signal integrity

Conditions: Fetal Distress

Summary: this project is set up to advance and integrate the established mathematical principles of oxygen saturation to model with increasing accuracy the "body in a body" problem of fetus in mother; similar to existing pulse oximeters,

the investigational device is a non-invasive fetal pulse oximeter that measures fetal arterial pulse signal using safe, noninvasive, transabdominal near-infrared spectroscopy. the optical sensor will obtain fetal pulse oximetry signals. women will also undergo sonographic evaluation to assess distance from maternal skin to fetal tissue and to confirm fetal presentation and position. there is no change to standard of care procedures for fetal heart rate monitoring. the fetal heart rate that will be monitored with the investigational device will be used for research purposes only. results will not be used to guide or alter patient management.

Eligibility criteria:
inclusion criteria: 1. pregnant women with singleton pregnancies, vertex presentation 2. age ≥ 18 years 3. healthy women ≥ 28 weeks gestation undergoing either non-stress test (nst) or biophysical profile (bpp) or 4. healthy women ≥ 37 weeks in labor 5. vertex presentation exclusion criteria: 1. age \<18 years 2. multiple gestation ( twins, triplets) 3. presentation other than vertex 4. \< 28 weeks of gestation
shanghai meiji health science and technology co., ltd

Conditions: Over Weight People

Summary: investigators performed a randomized double-blind trial to determine the effects of long-term nnex ingestion in patients with overweight or obesity. ninety-five participants (23\<bmi\<30 kg/m2) were randomly allocated to three groups: a control group, a 1 g/day nnex group, and a 2 g/day nnex group. the effects of the consumption of 2 g/day or 1 g/day nnex for 12 weeks on indices of adiposity and fasting blood metabolic parameters were compared with those of no consumption of nnex.


Eligibility criteria:
inclusion criteria: * has a body mass index (bmi) of 23-30 kg/m2 * has no history of using any antidiabetic medication * absence of liver, kidney, or heart disease * absence of food allergy and daily tea consumption \<2 l * meet all of the above criteria and to follow the instructions given during the study. exclusion criteria: * testing delayed for \>1 week without justification * difficulty attending the hospital on the required days * lack of data regarding the times of beverage consumption for over 5% of the study * abnormal overeating * test results believed to be unreliable because of the lack of provision of diet and exercise reports during the fasting period * difficulty drawing blood * poor confidence in the test data
study to determine if contacting patients with mtc more frequently results in earlier detection and treatment of signs and symptoms of aes and thus a decrease in the percentage of time patients experience aes during first 12 months on vandetanib treatment

Conditions: Locally Advanced or Metastatic Medullary Thyroid Cancer; Medullary Thyroid Cancer

Summary: the purpose of this study is to evaluate the effect of patient outreach program on the proportion of time patients with mtc experience moderate or severe aes during first 12 months of treatment with vandetanib


Eligibility criteria:
inclusion criteria: * provision of informed consent prior to any study specific procedures * female or male aged 18 years and over * previously confirmed histological diagnosis of unresectable, locally advanced or metastatic hereditary or sporadic mtc. documentation must be provided in patient's medical chart * who or ecog performance status 0-2 * negative pregnancy test (urine or serum) for female patients of childbearing potential exclusion criteria: * unstable brain metastases or spinal cord compression that require treatment, unless treated at least 4 weeks before first dose and stable without steroid treatment for 10 days * major surgery within 4 weeks before randomization * the last dose of prior chemotherapy received less than 3 weeks prior to randomization * radiation therapy not completed prior to the first dose of vandetanib * significant cardiac event, superior vena cava syndrome, nyha classification of heart disease ≥2, within 12 weeks before randomization, or presence of cardiac disease that in the opinion of the investigator increases risk of ventricular arrhythmia * creatinine clearance \<30 ml/min (calculated by cockcroft-gault formula),patients with moderate renal impairment, defined as creatinine clearance ≥30 to \<50 ml/min, must start vandetanib at a reduced dose of 200 mg

Keywords: medullary thyroid cancer locally advanced metastatic vandetanib patient outreach
randomized controlled trial of stress reduction and lifestyle modification for ulcerative colitis

Conditions: Ulcerative Colitis

Summary: patients with ulcerative colitis often suffer significant limitations to their quality of life, which are also conditioned by particular stress and psychosocial accompanying symptoms of the disease. a multimodal program for stress-reduction and lifestyle-modification has been shown to be effective in promoting the quality of life. the study will examine the promotion of the quality of life of patients with ulcerative colitis and the positive influence on stress, psychological symptoms and physiological parameters. 92 patients with ulcerative colitis will be randomized in an intervention group and a control group for 10 weeks. the primary outcome is the disease-specific quality of life, the secondary outcomes are stress, psychological symptoms, inflammatory parameters, disease activity parameters, bowel parameter and the microbiome.


Eligibility criteria:
inclusion criteria: * 18 to 75 years * diagnosis of ulcerative colitis * currently in remission, remission not longer than 12 months * limited quality of life or increased subjective stress level exclusion criteria: * infectious or chronic active ulcerative colitis * taking glucocorticoids or immunosuppressants within the last 3 months, except stable medication using azathioprine * colectomy * serious psychological disorder (for example: major depression, addiction, schizophrenia) * serious comorbid somatic disease (for example: diabetes mellitus, oncological disease) * pregnancy * participation in stress reduction program or clinical studies to psychological interventions
a safety, tolerability and pharmacokinetic study of leo 29102 in subjects with atopic dermatitis

Conditions: Atopic Dermatitis

Summary: the purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of 7 days treatment with leo 29102 in adult patients with atopic dermatitis.


Eligibility criteria:
inclusion criteria: * age 18-55 years * atopic dermatitis of 850-1700cm2 * in good health criteria for exclusion: * co-morbid conditions * hepatic dysfunction * clinical infection * immunocompromised status * clinically significant illness * use of immunomodulating treatment * medications related to respiratory system or to heart rhythm
b-cryptoxanthin and phytosterols on bone remodeling and cardiovascular risk factors

Conditions: Postmenopausal Disorder

Summary: we, the investigators, aim to study, in vitro and in vivo, the bioavailability of added b-cryptoxanthin and phytosterols and evaluate in vivo its effect on biochemical markers of bone remodelling and cardiovascular risk. specifically, we will 1) assess the stability in the food and the bioavailability of b-cryptoxanthin in the presence of phytosterols (absorption modifiers) by using a complementary approach; in vitro and in vivo studies; and 2) we will study in post-menopausal women (target group) the biological effect (bioefficacy) associated with the regular consumption of modified milk-based fruit beverages (containing b-cryptoxanthin and phytosterols) by assessing changes in biochemical markers of bone turnover and cardiovascular risk.


Eligibility criteria:
inclusion criteria: * post-menopausal women, 45-60 years old exclusion criteria: * dieting * food allergy (to any components provided) * hormone replacement therapy * cholesterol lowering drugs, antiresorptive or anabolic bone drugs * calcium and vitamin d supplements * soybean products * vitamin-mineral supplements * fibre supplements * commercially available enriched foods (i.e. w-3, phytosterols,carotenoids,...)

Keywords: b-cryptoxanthin cholesterol bone markers osteoporosis cardiovascular risk post-menopausal women
assessing perceptual effects of interactive tasks

Conditions: Amyotrophic Lateral Sclerosis

Summary: in this study, we will evaluate how solo, naive listeners perceive the speech of people with amyotrophic lateral sclerosis (als) and age-matched speakers produced across interactive and non-interactive contexts with an unfamiliar, naive interlocutor.

listeners will hear recorded speech of pals and age-matched speakers and indicate what they heard. recorded speech consists of vowels and consonants produced in non-interactive and interactive tasks. the perceptual judgements will be compared to see whether interactive contexts have similar perceptual effects across the two groups. plans for assignment - this is a single group study in which all participants will engage in the same tasks. delivery of intervention: solo listeners will participate in this study in a remote, asynchronous format. they will be recruited using the online participant recruitment platform prolific © and will use their own laptop/computer and headphones. adequacy of sample size: we will use n = 1300 listeners to achieve 80% power at alpha of .05 to detect between group differences with the assumption of medium effect sizes (cohen's f = 0.3). adequacy of analyses: the proposed statistical analyses (generalized mixed effects regressions) are standard and will be used to analyze the effect of the intervention on the outcome measures described below.

Eligibility criteria:
inclusion criteria: * passing the remote hearing screening * having no known speech, language or neurological disorders per self-report * being a native monolingual speaker of american english * having no experience communicating with people with dysarthria * being between the ages of 18 and 65. exclusion criteria: * none - if volunteer meets the inclusion criteria, then they will be enrolled
gut microbiome and serum metabolome alterations in adhd patients

Conditions: Attention-deficit/Hyperactivity Disorder

Summary: host-microbe interactions play a key role in brain development and function and in the etiology of neurodevelopmental disorders. attention-deficit/hyperactivity disorder (adhd) is a heterogeneous disorder that affects 1 in 20 children and results in poor life-time outcomes. however, the etiology of adhd is unclear and its diagnosis and treatment are still challenging. different factors reported to be associated with the risk of developing adhd and/or linked to different adhd manifestations have also been linked to shifts in gut microbiota composition, suggesting a link between the microbiota and the disorder. here, we will perform a metagenome-wide association study and serum metabolomics profiling in a cohort of control and adhd, 6-15 years, chinese individuals. we aim to identify adhd-associated gut microbial species linked to changes in circulating metabolites. we also aim to find the possible intervention strategy in adhd by targeting the gut microbiota.


Eligibility criteria:
inclusion criteria: diagnoses of the children with adhd were made in xijing hospital according to criteria described in the diagnostic and statistical manual of mental disorders (dsm-iv). children with adhd had an iq score above 70. exclusion criteria: children who had a past history of or were currently affected by neurological diseases, including convulsive disorders or brain damage; or who had any evidence of comorbid psychiatric conditions, such as tourette's syndrome, iq below 70, pervasive developmental disorder (autism), bipolar disorder, psychosis, language difficulties or learning disorders (reading disorders, mathematics disorders and disorders of written expression).

Keywords: attention-deficit/hyperactivity disorder circulating metabolites metagenome
transversus abdominis plane block in the management of acute postoperative pain syndrome after caesarean section

Conditions: Pain

Summary: in many countries, caesarean section (cs) rates have been increasing. the international literature is unclear regarding the analgesic efficacy of the transversus abdominis plane block (tapb) after a cs. in particular, no clinical trials exist in which the correct method of performing this block has been matched with the obtained analgesic effect after a cs. the primary goal of the study was to determine whether a correctly performed ultrasound-guided tapb (usg-tapb) could provide patients who underwent a cs with better control of acute postoperative pain during the first 72 hours after surgery

transversus abdominis plane block (tapb) is a regional anesthetic technique that can provide analgesia for lower abdominal surgical procedures. previous meta-analyses and recently published clinical trials have demonstrated promising results for this technique when it is used as part of multimodal postoperative pain treatment, but no consensus exists regarding the potency of this type of anesthetic procedure for analgesia after a cs. the primary goal of the study was to determine whether a correctly performed ultrasound-guided tapb (usg-tapb) could provide patients who underwent a cs with better control of acute postoperative pain during the first 72 hours after surgery. in this study, the correct execution of an usg-tapb was verified, and then the procedure was matched with the obtained analgesic effect after a cs. the secondary aims were to determine whether usg-tapb could ensure a decline in postoperative requests for opiates and fewer opiate-related side effects, the return of faster bowel function, and shorter recovery time without generating critical hemodynamic changes.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) physical status i-iii * caesarian section. the pfannenstiel incision was performed. exclusion criteria: * body mass index (bmi) \>35 * allergy to local anesthetics * skeletal and/or muscle abnormalities of the spine * primary and/or secondary neurological diseases * psychiatric diseases * history of chronic pain and/or neuropathic disorders * history of drug abuse * state of sepsis * infection and/or tumors within the skin on the back * primary or secondary coagulopathies * pre-eclampsia or eclampsia.
complement activation during hemodialysis in atypical hemolytic uraemic syndrome as underlying kidney disease

Conditions: Atypical Hemolytic Uraemic Syndrome

Summary: atypical hemolytic uraemic syndrome is caused by defects in the regulating factors in the alternative pathway of the complement system. triggering can cause an uncontrolled complement activation with endothelial damage and thrombotic micro-angiopathy, especially in the kidneys. this can result in endstage renal failure. complement activation during hemodialysis has been described as a result of contact between blood and the dialysis membrane. our hypothesis is that patients with atypical hemolytic uraemic syndrome have a stronger complement activation during hemodialysis than patients with another underlying kidney disease. this could be a reason to treat patients with endstage renal failure due to atypical hemolytic uraemic syndrome preferentially with peritoneal dialysis instead of hemodialysis.


Eligibility criteria:
inclusion criteria: * cases: endstage renal failure due to atypical hemolytic uraemic syndrome treated with hemodialysis. * controls: endstage renal failure due to a non complement consuming nephropathy treated with hemodialysis.
clinical study of huperzine a in the treatment of patients with hypertensive cerebral hemorrhage

Conditions: Neurosensory Disorder

Summary: 1. to evaluate the effectiveness of huperzine a injection in the treatment of brain injury in patients with hypertensive cerebral hemorrhage； 2. to evaluate the safety of huperzine a injection in the treatment of brain injury in patients with hypertensive cerebral hemorrhage。

a randomized, controlled, single-center, exploratory clinical research method was used. in the treatment plan, the experimental group used basic treatment + huperzine a, and the control group only used basic treatment, with a total of 20 cases. to evaluate the effectiveness and safety of huperzine a injection in the treatment of brain injury in patients with hypertensive cerebral hemorrhage.

Eligibility criteria:
inclusion criteria: 1. aged from 18 to 75 years old(including 18 and 75 years old), males or females; 2. first onset, clinical diagnosis of hypertensive intracerebral hemorrhage, and ct confirmed that the amount of hemorrhage is between 15ml-50ml, the bleeding site is the basal ganglia, the bleeding has not penetrated into the lateral ventricle, and non-surgical patients； 3. those with obvious neurological dysfunction after the onset, 5≤gcs≤15 or nihss≥6； 4. admission within 72 hours after the onset of the disease, and no significant enlargement of the hematoma within 24 hours after admission (hematoma enlargement ≤ 5ml)； 5. the patient/family knows and signs the informed consent form voluntarily. exclusion criteria: 1. cerebral hemorrhage caused by cerebral aneurysm, brain tumor, brain trauma, cerebral parasitic disease, cerebrovascular malformation, abnormal blood vessel network at the base of the brain, cerebral arteritis, blood disease, metabolic disorder and other diseases confirmed by examination; 2. patients with enlarged hematoma found within 24 hours after admission (the volume of enlarged hematoma\> 5ml); 3. patients with simple transient ischemic attack, lacunar infarction, subarachnoid hemorrhage and ischemic cerebral infarction; 4. patients who use anticoagulant drugs for a long time; 5. patients with platelet count \ 1.4 at admission and abnormal blood coagulation function; 6. the measured value of homocysteine at admission is higher than 15μmol/l; 7. patients who need surgical treatment (including ventricular drainage); 8. patients with severe primary diseases such as cardiovascular, liver (alt or ast\>1.5 times the upper limit of normal), kidneys (bun\>1.5 times the upper limit of normal and cr\>upper limit of normal), endocrine system and hematopoietic system; 9. those who are allergic to protein and test drugs; 10. people who are dependent on drugs or alcohol; 11. intended pregnancy or women of childbearing age with positive pregnancy test and lactating women; 12. participated in other clinical trials within the past 3 months; 13. patients considered by the investigator to be inappropriate to participate in clinical trials.
decompensation of cirrhosis and iron metabolism

Conditions: Cirrhosis

Summary: iron is a crucial metal whose metabolism is tightly regulated. iron deficiency or iron overload are both deleterious at the cellular, organic and systemic levels. in line with the major role of the liver in iron homeostasis, links between iron metabolism and acute on chronic liver failure have been highlighted. nevertheless, due to the difficulty of accurately assessing iron metabolism in this situation, therapeutic intervention on iron metabolism in this setting is currently not codified. a better understanding of these mechanisms is therefore essential, in particular by characterizing the impact of exposure to non-transferrin-bound iron in acute on chronic liver failure on short-term mortality. overall, a better understanding of the physiopathological mechanisms of iron should allow to optimize the martial balance in this condition and also improve therapeutic approaches.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years old. * diagnosis of cirrhosis, previously known or not, of any etiology, histologically proven or not. * hospitalization for acute on chronic liver failure: * ascites decompensation. * or spontaneous infection of the ascites fluid (defined as pnn \> 250/mm3 of ascites). * or digestive hemorrhage related to portal hypertension (digestive fibroscopy showing active bleeding or stigmas of recent bleeding from esophageal and/or gastric varices). * or hepatic encephalopathy (clinically defined +/- increase in ammonia and/or by electroencephalogram and classified in stages according to west-haven). * or hepato-renal syndrome (hrs-aki criteria, easl 2018). * or bacterial infection (defined by a bacteremia identified by at least one blood culture and/or an infectious site authenticated on imaging). * or acute alcoholic hepatitis (histologically proven or not). * non-opposition of the patient, relative or legal representative. exclusion criteria: * treatment with oral or intravenous iron in the month prior to hospitalization. * implementation of a tips in the month prior to admission. * presence of hepatocellular carcinoma with an expected survival \< 3 months or any other progressive cancer. * adult person subject to legal protection (safeguard of justice, curatorship, guardianship), person deprived of liberty.

Keywords: decompensation of cirrhosis iron metabolism
evaluation of brain metastases treated with stereotactic radiotherapy using dynamic [18f]fdg pet

Conditions: Brain Metastases

Summary: the purpose of this study is to evaluate the clinical usefulness of dynamic \[18f\]fdg pet imaging in assessing brain metastasis post stereotactic radiotherapy to separate true progression from the treatment-related changes.

after being informed about the study and potential risk, all participants giving written informed consent will be screened to determine if participant being referred fits eligibility criteria for the study, under of the supervision of the radiation oncologist. if a participant agrees to participate in this study, they will receive three additional imaging sessions (the dynamic pet scan). the first session will occur prior to starting treatment; the second session will occur at about 10 weeks post treatment; the third session will occur at first concern of progression at treated lesions or 12 months post-treatment, whichever comes earlier. these scans will be scheduled in addition to the participant's regular follow-up scans and appointments.

Eligibility criteria:
inclusion criteria: * age 18 or older. * willing and able to provide consent. * ecog 0-2. * life expectancy ≥12 months. * creatinine clearance ≥30 ml/min within 28 days prior to registration. * at the discretion of the treating oncologist, it is believed that at least 1 lesion (or resection cavity) is best managed with srs/sfr exclusion criteria: * pregnant or nursing women. * men or women of childbearing potential who are unwilling to employ adequate contraception. * inability to complete a brain mri. * known allergy to gadolinium. * inability to complete a pet scan. * uncontrolled diabetes mellitus. * primary germ cell tumour, primary cns tumour, or lymphoma * srs/fsrt is no longer indicated for any bms * must be able to read and write english

Keywords: dynamic f-18 fdg pet, brain metastases stereotactic radiation radio-necrosis pseudo-progression
partial meal replacement and inulin in obese women

Conditions: Obesity

Summary: the objective of this study was to test the efficacy of a partial meal replacement added with vitamins, minerals and inulin on weight reduction, blood lipids and micronutrients intake in obese mexican women


Eligibility criteria:
inclusion criteria: * bmi \> 25 kg/m 2 exclusion criteria: * pregnant * lactating * diagnosed with diabetes * diagnosed with hypertension * fasting glucose ≥126 mg/dl * blood triglycerides ≥400mg/dl